Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Current Assets (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Current Assets data on record, last reported at $208.1 million in Q3 2025.

  • For Q3 2025, Current Assets rose 311.67% year-over-year to $208.1 million; the TTM value through Sep 2025 reached $208.1 million, up 311.67%, while the annual FY2024 figure was $119.0 million, 149.12% up from the prior year.
  • Current Assets reached $208.1 million in Q3 2025 per TNXP's latest filing, up from $143.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $208.1 million in Q3 2025 and bottomed at $25.3 million in Q2 2024.
  • Average Current Assets over 3 years is $85.5 million, with a median of $51.3 million recorded in 2023.
  • Peak YoY movement for Current Assets: crashed 64.05% in 2024, then skyrocketed 467.62% in 2025.
  • A 3-year view of Current Assets shows it stood at $47.8 million in 2023, then skyrocketed by 149.12% to $119.0 million in 2024, then soared by 74.85% to $208.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $208.1 million in Q3 2025, $143.5 million in Q2 2025, and $149.6 million in Q1 2025.